2-[[butylhydroxyphosphinyl]methyl]pentanedioic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[butylhydroxyphosphinyl]methyl]pentanedioic acid
• 英文别名: 2-[(Butylhydroxyphosphinyl)methyl]pentanedioic acid；2-[[butyl(hydroxy)phosphoryl]methyl]pentanedioic acid
• 化学式: C₁₀H₁₉O₆P
• 分子量: 266.231
• InChiKey: MIINQJNPWDYQGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  butyl[2,4-di(benzyloxycarbonyl)butyl]phosphinic acid 以 水 为溶剂， 反应 4.5h， 以to give 2-[(butylhydroxyphosphinyl) methyl]-pentanedioic acid (4, R=n-butyl) (0.75 g, 43%) as a clear and colorless viscous oil的产率得到2-[[butylhydroxyphosphinyl]methyl]pentanedioic acid
  参考文献：
  名称：

  Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors

  摘要：

  本公开涉及一种抑制血管生成的方法，包括向需要该方法的患者施用N-乙酰化的α-链接酸性二肽酶（NAALADase）抑制剂，以及包含抗血管生成有效量的NAALADase抑制剂和药学上可接受的载体的药物组合物。

  公开号：

  US06395718B1

文献信息

• PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
  申请人：Purdue Research Foundation

  公开号：US20160067341A1

  公开（公告）日：2016-03-10

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

  本文描述了用于传递治疗、诊断和成像剂的前列腺特异性膜抗原（PSMA）结合共轭物。本文还描述了含有它们的药物组合物以及使用这些共轭物和组合物的方法。还描述了用于制造这些共轭物和含有它们的组合物的过程。
• Naaladase inhibitors for treating retinal disorders and glaucoma
  申请人：——

  公开号：US20030036534A1

  公开（公告）日：2003-02-20

  The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.

  本发明涉及使用NAALADase抑制剂治疗视网膜疾病或青光眼的药物组合物和方法。
• Certain dioic acid derivatives useful as NAALADase inhibitors
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US06025344A1

  公开（公告）日：2000-02-15

  The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.

  本公开涉及二肽酶抑制剂，更具体地说，涉及抑制N-乙酰化α-连接酸性二肽酶（NAALADase）酶活性的新磷酸酯衍生物、羟基磷酰衍生物和磷酰胺衍生物，包括这些衍生物的药物组合物，以及使用这些衍生物抑制NAALADase活性并治疗前列腺疾病的方法，尤其是使用本发明的化合物来抑制前列腺癌细胞的生长。
• Inhibitors of NAALADase enzyme activity
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US06025345A1

  公开（公告）日：2000-02-15

  The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.

  本公开涉及二肽酶抑制剂，更特别地，涉及使用磷酸酯衍生物、羟基磷酰衍生物和磷酰胺衍生物的新方法来抑制N-乙酰化.α.-连接的酸性二肽酶（NAALADase）酶活性，并治疗前列腺疾病，特别是使用本发明的化合物抑制前列腺癌细胞生长。
• NAALADase inhibitors
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US06046180A1

  公开（公告）日：2000-04-04

  The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives to inhibit NAALADase activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.

  本公开涉及二肽酶抑制剂，更特别地，涉及抑制N-乙酰化α-连接酸性二肽酶（NAALADase）酶活性的新磷酸酯衍生物、羟基磷酰衍生物和磷酰胺衍生物，包括这些衍生物的药物组合物，以及使用这些衍生物抑制NAALADase活性和治疗前列腺疾病的方法，尤其是利用本发明化合物抑制前列腺癌细胞生长。